Literature DB >> 9748560

Clinical applications of anticancer drugs targeted to topoisomerase II.

K R Hande1.   

Abstract

Agents which 'poison' the enzyme topoisomerase II, have proven to be useful drugs for cancer treatment. Six antineoplastic drugs, which target topoisomerase II (doxorubicin, daunorubicin, idarubicin, mitoxantrone, etoposide and teniposide) are currently approved for clinical use in the United States. In this paper, the strategies and goals of cancer chemotherapy are summarized for the non-clinician. The use, pharmacology and toxicity of each of the six currently approved topoisomerase II inhibiting agents are reviewed.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9748560     DOI： 10.1016/s0167-4781(98)00134-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  61 in total

1.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression.

Authors:  Daniel R Rhodes; Jianjun Yu; K Shanker; Nandan Deshpande; Radhika Varambally; Debashis Ghosh; Terrence Barrette; Akhilesh Pandey; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

3.  Pharmacokinetics, antitumor and cardioprotective effects of liposome-encapsulated phenylaminoethyl selenide in human prostate cancer rodent models.

Authors:  Jeong Yeon Kang; Mathew Eggert; Shravanthi Mouli; Ibrahim Aljuffali; Xiaoyu Fu; Ben Nie; Amy Sheil; Kendall Waddey; Charlie D Oldham; Sheldon W May; Rajesh Amin; Robert D Arnold
Journal:  Pharm Res       Date:  2014-08-27       Impact factor: 4.200

4.  Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.

Authors:  Jennifer S Dickey; Neil Osheroff
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

5.  The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Biochemistry       Date:  2006-03-07       Impact factor: 3.162

6.  Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  ACS Chem Biol       Date:  2013-09-30       Impact factor: 5.100

7.  Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.

Authors:  Amanda C Gentry; Steven L Pitts; Michael J Jablonsky; Christian Bailly; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2011-03-28       Impact factor: 3.162

8.  Gene expression levels of human shelterin complex and shelterin-associated factors regulated by the topoisomerase II inhibitors doxorubicin and etoposide in human cultured cells.

Authors:  Masahiro Kato; Masahiro Nakayama; Minako Agata; Kenichi Yoshida
Journal:  Tumour Biol       Date:  2012-12-18

9.  (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases.

Authors:  Omari J Bandele; Neil Osheroff
Journal:  Chem Res Toxicol       Date:  2008-02-23       Impact factor: 3.739

10.  Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.

Authors:  Nicolas Tsavaris; Andreas Lazaris; Christos Kosmas; Panagiotis Gouveris; Nikolaos Kavantzas; Petros Kopterides; Thomas Papathomas; George Agrogiannis; George Arapogiannis; Haralambos Zorzos; Vassiliki Kyriakou; Efstratios Patsouris; Efstathios Patsouris
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-16       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.